Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
67.10
-1.90 (-2.75%)
At close: Nov 16, 2026, 4:00 PM EST
65.60
-1.50 (-2.24%)
After-hours: Nov 16, 2026, 7:58 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Zanzalintinib’s PDUFA is expected in early March 2027, with STELLAR-304 data targeted for Q1 2027. CRC trials and a planned second wave of studies underpin a broad growth opportunity, while a third franchise remains a strategic priority.

Operator

—Glad to have with us to kick off the afternoon sessions, we have Andrew Peters from Exelixis. Andrew, thanks for joining us.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Hey, Steve. Thanks for having us.

Operator

Any opening statements you want to make before we jump into Q&A?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Thanks for the invite. Great meetings today. Been really fun engaging with investors. As always, going to be making some forward-looking statements today, so please see relevant disclosures around risks in our business in SEC filings. Right now is a really exciting time for Exelixis. We're at that transition point as our next franchise, our second franchise, zanzalintinib, we have a PDUFA date in March of next year, early March of next year. We're seeing that transition from single-product company with cabo to multi-franchise company with cabo and zanza, and then off to the races from there. Just really excited, full speed ahead on just the commercial execution, clinical execution, and then everything we're doing from both an early pipeline perspective.

Really the last thing I would say that is surprising to some is this dynamic or through line that always is at Exelixis is we run the company like a business and not a biotech. It is about execution, it is about discipline, it is about prioritization. All of that just is really good time at Exelixis right now.

Operator

Okay, perfect. Let us jump into zanza. I will probably spend most of my time on this. You just extended the top-line disclosure for STELLAR-304. This is the phase III study in non-clear cell renal cancer. That is now expected to happen first quarter of next year. Can you just talk about how you are thinking about this delayed event accrual, and what investors should expect to see in a press release when you guys communicate this top-line data?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. Simply put, we are tracking events as they come in real time, and as we see the accumulation of events moving towards certain number of events, provide clinical cutoff, clean the data, top line. When we saw a clinical cutoff based on the event rates going to happen closer to year end, that is why we guided to—

Operator

Okay.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

—First quarter. Simple as event rates coming in a little slower as we triangulated what that was expecting, that is what drove the timing. In terms of the press release, what is not going to be in there, honestly, I do not know. I have not written the press release yet. In the past, we have included a lot of data. In the past, we have included just some top line. There is a lot of sausage-making, as you can appreciate, in terms of what gets shared and how around medical conferences and all of that. But our goal, our hope is to generate as robust of a dataset as we can, get that filed, and get into patients as soon as we can.

Operator

Okay. I know we saw updated phase II Nivo Cabo data in non-clear cell at ASCO this past year, or this year actually. I think frontline response rate somewhere in the mid-40% range. PFS was 11 months. Maybe that trends a bit higher when you exclude some of the second-line patients. How do you think about those as relevant efficacy benchmarks that you need to clear in order to commercially differentiate zanza from cabo in this setting specifically?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. That's the eternal debate, isn't it, in biotech, is how do you compare apples and oranges, single arm, single center phase II to large global randomized phase IIIs? That's really the challenge and is really actually the reason why we started 304 in the first place, is for variety of reasons, all drugs with labels in RCC have those inclusive or exclusive of non-clear cells, so clear cell and non-clear cell. There's actually never been a large global randomized study in this space. We thought what we had a chance to do with 304 is really plant a flag in the ground and define with level 1 evidence a standard of care.

What that does is, right now patients are treated really in a hodgepodge of different therapies, and so use is somewhat driven by guidelines, which again, are driven by single arm unrandomized data, which are complicated in the single center or the sort of patients that are enrolled. There's just a lot of dynamics that go into it. What we have a chance to do is establish with level 1 evidence, with large randomized phase III data, to go in and define the standard of care. I think it's probably less useful to look at small-end datasets or datasets where perhaps a skew of patients, favorable, intermediate, all of those sorts of dynamics. It's just hard to compare smaller studies to large global randomized studies.

Operator

Okay. You just pointed out the lack of specificity that exists between non-clear cell and clear cell with regards to frontline labeling today. Would you think that there's the potential for a similar phenomenon to play out here from a labeling perspective for nivo zanza?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. Honestly, it is probably too early to speculate on something like that. We will have to see the data first and really let the data kind of show us what we are looking at.

Operator

Okay. Just maybe sticking with RCC, we saw the LITESPARK-011 and 012 data at the ESMO meeting a couple weeks ago. Would be curious if there was anything incremental in those presentations that you found to be of interest, specifically as it pertains to how you are thinking about Cabo sustainability in the second-line setting and how you are now trying to position zanza via the LITESPARK studies 033 and 034.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. Certainly, I think the LITESPARK 12 data showed us that the door in kind of the de novo metastatic frontline space is wide open. We have talked about this. We are anticipating kind of a second wave of zanza trials to start shortly, and one of those will almost certainly be in kind of that frontline metastatic space. LITESPARK 12, we think there is a real opportunity there. We are going to take those learnings, take the learnings from our own experience, say, with COSMIC-313, and then try and understand and let the biology drive what are the appropriate combinations, orthogonal mechanisms, et cetera, to kind of drive that confidence in a successful frontline study. As it relates to LITESPARK 11, did not really hear a whole lot new at ESMO.

Obviously, with the label, we had known that positive on PFS, lacking a statistically significant survival advantage, and really, that is one of the dynamics that we kept hearing. In oncology, there is this everlasting discussion or debate around, is it better to combine or sequence? That is certainly the case here. If you look at, say, monotherapy TKIs, Cabo, in that second line, you will get, say, 10, 11 months PFS, and monotherapy belzutifan, you will get kind of five, six months. So actually, if you are sequencing therapies, that absolute PFS is probably actually a little bit longer than what you would expect with that combination, and you do not have that additive tox of the doublet, where almost half of those patients were discontinuing one of the two drugs anyway.

The other dynamic that we've talked about, kind of that comes up in our conversations with prescribers, is this idea that if some patients ultimately will get len-belz in that second line, what it likely means is they wouldn't have gotten len-pem in the first-line setting. That opens the door again to continuing to drive share for cabo-nivo in the frontline. As we have long talked about, that's one of the dynamics that we've been driving for since 9ER came out, just because that frontline opportunity from a duration perspective, from the number of patients perspective, is just larger. It's actually kind of playing out that way—

Operator

Okay.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

—S o far.

Operator

I know there was also a trials-in-progress poster that you guys presented at ESMO for LITESPARK 34. It showed the zanza dose that you're using in that trial is now 60 mgs, right, which is lower than the 100 mg dose that you used in the first tranche of studies. Is this a dose that reflects optimization with belzutifan specifically, or should we expect to now kind of see you guys pursue lower zanza doses across kind of the remaining phase III STELLAR trials that you're looking to—

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. So kind of broadly speaking, I think we optimize the zanza dose or the dose of any agent that we're looking at for the indication, the combination, and the line of therapy.

It's a playbook that we and others have used, certainly kind of what we did with Cabo. As you look at combination partner, and in the background, we're constantly evaluating exposure response and all of that stuff, that ultimately drives that decision. I'd say there's not kind of one set dose going forward. It's how do we optimize it to run a successful study that maximizes the clinical benefit risk for patients. As example that I always give is, again, kind of the lessons learned in the Cabo lens, as we went from second line to first line in RCC, we lowered the dose. Probably took a little bit off the top in terms of efficacy, but because those are earlier line patients, that overall tolerability, quality of life dynamic was really important.

Apply that to something like colorectal cancer, where we looked at 100mg in 303. These are late-line patients where efficacy is kind of the paramount driver of decision-making. Then you contrast that with a study like STELLAR-316, which is looking at that post-definitive therapy, post-adjuvant space, where again, kind of that clinical benefit risk dynamic is just a little bit differently, much earlier line patients versus much later line patients. You'd imagine we'd look at a lower dose of zanza there, presuming we have comfort in a lot of that exposure response work, target coverage, distribution, all of that, which we've continued to generate data in the background.

Operator

Okay. I know the phase I dose escalation data that we've seen, I guess both as a single agent with zanza and also in combination with the atezo. There wasn't a 60 mg dose that was specified in that schema. Just, is there anything that you can say regarding kind of what that 60 mg dose means in terms of PK/PD implications or the level of target coverage that you're able to achieve, maybe relative to standard Cabo dosing?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. Kind of short answer is we're very comfortable with that dose, all the kind of exposure response coverage. What we've published so far on, I think you said 40 and 60, 80, or 40, 80, whatever you mentioned, we've generated a lot of data subsequent to that, including with 60. We have a lot of information that we're using to inform these decisions.

Operator

Okay. Maybe we can shift gears to colorectal. You have zanza, atezo, that combo in front of FDA. This is seeking approval in third-line plus patients. The PDUFA was extended to accommodate an agency request for more data. Maybe you can just kind of speak to the company's broader level of confidence in the regulatory path forward and broader labeling prospects as it pertains to both liver met and non-liver met patients.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I mean, we are excited about the data. Anytime you can show a survival advantage against the standard of care, is something to be especially excited about. Our conversations with prescribers and KOLs kind of echo that sentiment with the potential ability to have a treatment option for patients that is chemo-free, checkpoint-containing, active across pretty much every subgroup, including patients who had seen prior Avastin. Those are the sorts of things that we hope to commercially differentiate when we eventually launch.

As it relates to kind of conversations with regulators, for obvious reasons, we are not going to get into specifics there. What I would say is your question on subgroups and liver met , non-liver met , historically, when labels have been limited to kind of subgroup analysis, I tend to think of examples like the PARPs, where you had a single subgroup driving the effect size across a broader population.

What the 303 data show is that is in fact not the case. You basically similarly or broadly active across every one of those subgroups, if you look kind of at the forest plots. The liver met , non-liver met delineation on primary endpoint was really kind of informed on empiric kind of post-hoc data of some prior studies that we have seen. We kind of have since figured out it is probably much less biologically relevant than we had thought, given that we essentially won on ITT and it was not driven by any single subgroup. So, that breadth of data is certainly something that we are focusing on and excited to talk to patients and prescribers about.

Operator

Okay. What is your perspective on the commercial opportunity that a broad label could potentially unlock here? I know you kind of referenced it a little bit earlier, but where do you see zanza, atezo gaining share versus some of the other kind of third-line established standard of care regimens, like the SUNLIGHT regimen, for instance?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I think it's interesting. Colorectal's kind of a unique or, I don't want to say one-off, but it's a somewhat different dynamic than some other tumor types in that it's a pretty substantially community-based prescriber and patient community. What that functionally means is that utilization is probably more split than it may seem. I think we've said in the past it's about a third SUNLIGHT, a third TKIs, and a third kind of broader chemo. In that total market opportunity, looking at number of patients, duration, contemporary pricing, et cetera, is about $1.5 billion. Given that broad activity across all of the different subpopulations, our goal is to take share from each of those groups. It's not to compete against one or sub one.

We're going to be aggressive, we're going to be effective at taking share kind of across the board and really maximizing the potential there. I think one of the other things to kind of keep in mind around that CRC indication or that CRC franchise is that's when our approach strategically on continuing to invest in CRC really can pay dividends. One of the things that we've observed at ad boards or conferences like in ASCO, when we're having a conversation with a prescriber around 303, they're equally interested in 316.

Similarly, someone who's like, "Oh, this 316 study seems particularly innovative. Zanza's not really on my radar. Tell me about what you've learned in 303." That kind of echo chamber is something that is really building, and we want to kind of lay that foundation in colorectal cancer, not only for ZANSA, but everything else that we're doing at Exelixis. We want to ultimately build towards an RCC franchise, a NET franchise, a CRC franchise, and kind of be thought leaders across all of them.

Operator

Okay. Maybe we can talk about 316 for a minute. Again, this is the phase III study looking at zanza, I think, in combination with PEM as well as a couple of different arms, but it's an MRD-positive disease following adjuvant chemo. I guess the totality of clinical data that we've seen in this space, right, would suggest that MRD-guided de-escalation of therapy in this setting is validated. But none of the clinical data that we've seen today would suggest that MRD-guided treatment intensification has led to better outcomes. How do you just think about what we've seen thus far from a data perspective, and how you're kind of hoping to change that historical narrative?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I think that's one of the things I'm most excited about and most proud of what we're doing at Exelixis, is to kind of be on that cutting edge right now. The MRD positivity is actually a relatively new technology. When we saw the first top-line readout of 303 and got that understanding that colorectal was going to be a sensitive tumor type for zanza, we kind of sat down and it's like, "Okay, how do we continue to invest there?" At the same time, this Signatera test, the data that shows this absolutely incredibly wide difference between MRD-negative and MRD-positive patients, the Kaplan-Meier curves on DFS are just frankly striking. It showed that, as you said, if you're MRD negative, you're pretty confident your tumor's not going to recur.

Unfortunately, for that 20% or so of patients who are MRD positive, you're at a very, very high risk of your cancer returning, on the order of probably six months or so. That's really the selected population that we're targeting, is those patients who are at very high likelihood of relapse, that we've shown positive survival data in a much more heavily pre-treated population. You layer on, say, contemporary data sets from, say, like the IMvigor study.

in bladder cancer, which take a conceptually similar approach, and that kind of further adds to layer on there. As I mentioned before, it was really this idea of, can we take a tumor type that we know is sensitive to zanza, compare it to kind of current standard, which is watch and wait, or functionally placebo, and then interrogate whether zanza alone or zanza in combination with pembro can help delay that DFS period so the patients can live longer without their tumor returning? It's that idea that we think the biology tells us that sensitive tumor type, the data tell us that this is a sort of approach that can work in other areas, and we're kind of at the cutting edge here.

Candidly speaking, coming back to this idea of running the business, running Exelixis like a business and not a biotech, as we sat down and thought about how do we continue to invest in CRC, certainly there are opportunities to look earlier and earlier and frontline triplet combos or whatever they are. But from that return math perspective, the cost, the time, the PTS of doing something like that relative to a 316, where you're randomizing against placebo, that's the sort of opportunity that we really want to move quickly with. That's why we're excited to be kind of first there.

Operator

Okay. To be fair, I know a lot of the data that's been generated on this MRD-guided treatment intensification front has been really just chemotherapy, right?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I mean, I think it's just exactly that. There's obviously a lot of nuance with the population we're looking at is that post-definitive therapy group.

They're kind of completed treatment and all of that. But yeah, it's certainly something that I'm excited about and we're proud of to be first here.

Operator

Okay. Maybe another question related to the trial itself. I think the history of data that we have for oral TKIs when used as maintenance, right, there's a suggestion that compliance and persistency has been a challenge and sometimes rate-limiting in a lot of those studies. Is there anything that you're doing or perhaps can do in either STELLAR-316 or some of the other trials where you're looking at maintenance now, like in lung, for instance, to really make sure that this compliance and persistency issue doesn't become impactful on the data side?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I mean, I think you hit it perfectly. Obviously there's been positive data even in RCC for Sutent adjuvant that never really went anywhere because of the tolerability. So, it's certainly something we're focused a lot on, and I think it comes back to your earlier questions around appropriate dose as we move earlier on. Then I think it also comes down to this is kind of the idealized version of a TKI here, where the shorter half-life that zanza has not only allows that secret sauce, so to speak, from kinase inhibition coverage, and it's not just VEGF, but it's the MET, the AXL, the MER, some of those TAM kinases that can be synergistic with the immune system and checkpoint inhibition, all of that stuff.

But it's also the user-friendliness of that shorter half-life, which allows for titratability, shorter dose holds, all of those things that can allow patients to stay on drug longer, that I think we hope to ultimately translate to clinical benefit.

Operator

Okay. I know you guys have a kind of expanding STELLAR development footprint. Can't really cover all of it, but is there anything that you'd like to specifically highlight just before we leave zanza, leave STELLAR?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I mean, the excitement that you'll hear from us around zanza is kind of twofold. Obviously excited about the launch in CRC, the upcoming data for 304, but it's that kind of totality of opportunity. We take each individual indication and study, and we think that they're optimized studies to be successful, but in totality, have the potential to be much larger than Cabo.

Then you layer on that wave two of opportunities where we're looking at similarly well-designed large market indication trials where you're taking that opportunity set of zanza and increasing it substantially. The way that I think about it is, one of the questions that we got asked two, three years ago was, "How are you going to replace Cabo in 2031?" And we said, "Not only do we think zanza can replace cabo, but we can grow it from there." The seven pivotal studies that we've outlined have $5 billion plus in total opportunity. Apply some sort of reasonable PTS to each of those. We think they're well-designed studies. They should be high PTS studies. You get some sort of opportunity set for zanza. If we double the number of studies, and again, if we maintain that they're similarly well-designed, we're increasing that opportunity set for zanza.

We're doing it in a cost-efficient way by continuing to like this model of working with clinical collaborators where we can pay for half of the studies, which allow us to do twice as much with the same amount of capital. That's the sort of opportunity that we look forward to with zanza, and we want to continue to do. It's about taking each of those opportunities individually, but the totality of the opportunity set is really what gets us excited as well.

Operator

Okay. I know Cabo sales are obviously growing well. You've got another four years of exclusivity there that you just talked about, four plus. I guess as you think about the post-LOE transition from Cabo to zanza, what's your level of confidence as you kind of look at the timing of things now that you're going to be able to smooth that transition out in the absence of a sales trough? I guess, how much of a strategic priority is it internally to ensure that there isn't a revenue gap there in 2031 that needs to be filled? Is that something that guides your view of the world from a business development perspective?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

I'd say there's a bunch of things there. I mean, obviously, it's going to be about commercial execution, clinical execution, and data.

So, if the commercial execution, the clinical execution, and those cadence of readouts continues to go, that is going to inform the shape of that zanza revenue trajectory. As it relates to our strategic need for another product, I think the answer is yes and yes and yes. We have a high strategic desire and priority to bring in that third franchise, not necessarily because of that transition from cabo to zanza, but because the way we recognize and can truly take advantage of the scale that we have built, not only commercially but on the development side, is bring in that third franchise. Can that come from our internal portfolio? Yes. Can it come externally as well? Also yes. We are going to continue to invest and be opportunistic on both.

But we believe that the way we get to that next big inflection point as a company is with that third franchise. And so, what we also want to do in the backdrop is be appropriate stewards and shepherds of shareholder capital, and we recognize that there is no faster path to value destruction than bad BD or M&A.

We want to be aggressive and opportunistic, but also not do things that could hamper us from an opportunity set in the future or an investment opportunity in the future. And so, we have a high strategic desire, but also a really thick filter to make sure that next product that we bring in is one that we have conviction in from the biology perspective, and I think importantly, conviction in the commercial side. What I think surprises a lot of folks about Exelixis is the area that we spend the most time in and diligence and understanding these opportunities is probably more on the commercial side, because the reality of our business is it is tough to develop drugs. It is even tougher to develop drugs that are successful commercially. Me-too drugs that launch after the standard of care just generally do not really do well.

And so, we want to make sure that we are able to define and generate a dataset that leaves the opportunity to be a new standard of care in a market size, in a market opportunity that is sufficient that we can continue to grow. So, big strategic desire, but similarly, we want to make sure we are cautious with how we allocate capital.

Operator

Okay. Maybe just lastly, you talked about the external and potential internal opportunities there. The pipeline's been like a little bit of a work in progress for the last five years or so. How are you thinking about the current version of the pipeline, and what should we expect to learn from some of these earlier stage opportunities over the, say, next 12 months or so?

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yeah. I mean, it's really about generating a dataset that allows us to answer the question, are we going to start a pivotal study or are we going to kill the program? Prioritization and being somewhat ruthless about that dynamic is probably at the core of what we do and what we do best. If something doesn't look like it's going to make the cut from a differentiated opportunity and a large market indication, we'll just cut bait and start to invest in the next thing. Really, the next decision points are going to be, is this going to move into a pivotal study or not? If it moves into a pivotal study, do we think it'll be successful? If successful, will it generate meaningful revenue for us?

If the answer to all of those is no, we'll just invest in the next thing and the next thing and the next thing. That's how we view the overall internal pipeline, is can we generate a dataset quickly enough and robustly enough to get an idea of what that profile looks like to either invest in that next expensive phase of the process or just cut bait and move on to the next thing.

Operator

All right. I think we'll leave it there. I know you got a flight to catch.

Thank you, Andrew.

Andrew Peters
SVP of Strategies and Investor Relations, Exelixis Stifel

Yep. Thank you.

Operator

Thanks, everyone.